MannKind (MNKD) Posts Q4 Loss of 66c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Keeps MannKind (MNKD) at 'Underperform'; Afrezza Plans in Limbo Until CCO Hired
March 15, 2016 6:45 AM EDTRBC Capital reaffirms MannKind (Nasdaq: MNKD) at Underperform with a price target of $0.15 following Q4 results and update issued Monday night.
ANalyst Adnan Butt commented, While MNKD has an approved diabetes drug in its hands in Afrezza and technosphere platform could have value in future drug development, we would like to see execution on four fronts before... More
MannKind (MNKD) Appoints New Chief Commercial Officer; COO Martens Resigns
March 14, 2016 4:01 PM EDTMannKind Corporation (Nasdaq: MNKD) announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global... More
MannKind (MNKD) Shares Jump 17%
March 14, 2016 9:48 AM EDTMannKind (NASDAQ: MNKD) stock spiked 17% Monday morning.
